Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Accustem Sciences Inc.ACMSY · Entity 8467 | Director | December 01, 2021 | December 03, 2021 |
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Former Director | June 09, 2022 | June 09, 2022 |
| Hepion Pharmaceuticals, Inc.HEPA · Entity 8208 | Director · Chairman | February 19, 2024 | February 22, 2024 |
| OKYO Pharma LtdOKYO · Entity 6916 | Director | July 21, 2026 | August 07, 2026 |
| SYNERGY PHARMACEUTICALS, INC.SGYP · Entity 164269 | Director | July 04, 2018 | July 06, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Accustem Sciences Inc.
Report date December 01, 2021 · Filed December 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2031-08-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-12-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The holder of the option may exercise it on August 1, 2021 but must hold shares for a 12 month period post-exercise without resale. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2031-11-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-12-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed |
Filing footnotes · ownership attribution and instrument terms
F1: The holder of the option may exercise it on August 1, 2021 but must hold shares for a 12 month period post-exercise without resale.
Cardiff Oncology, Inc.
Report date June 09, 2022 · Filed June 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2024-06-09 | Direct | 125,317 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Other · Acquired 26,800 · Balance 125,317 F1: In connection with the Reporting Person's departure from the Board of Directors, the Compensation Committee accelerated the vesting of 26,800 stock options to June 9, 2022 from March 9, 2023. In addition, the Compensation Committee extended the expiration date of the stock options to June 9, 2024. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $7.98 · Expires 2024-06-09 | Direct | 125,317 |
Reported balance
After 2022-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-09 · Other · Acquired 22,000 · Balance 125,317 F2: In connection with the Reporting Person's departure from the Board of Directors, the Compensation Committee accelerated the vesting of 22,000 stock options to June 9, 2022 from June 10, 2022. In addition, the Compensation Committee extended the expiration date of the stock options to June 9, 2024. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.60 · Expires 2024-06-09 | Direct | 125,317 |
Reported balance
After 2022-06-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-06-09 · Other · Acquired 28,858 · Balance 125,317 F3: Expiration date of the stock options was extended to June 9, 2024. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2024-06-09 | Direct | 125,317 |
Reported balance
After 2022-06-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-06-09 · Other · Acquired 44,734 · Balance 125,317 F3: Expiration date of the stock options was extended to June 9, 2024. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $21.60 · Expires 2024-06-09 | Direct | 125,317 |
Reported balance
After 2022-06-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-06-09 · Other · Acquired 755 · Balance 125,317 F3: Expiration date of the stock options was extended to June 9, 2024. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $51.84 · Expires 2024-06-09 | Direct | 125,317 |
Reported balance
After 2022-06-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-06-09 · Other · Acquired 530 · Balance 125,317 F3: Expiration date of the stock options was extended to June 9, 2024. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $372.96 · Expires 2024-06-09 | Direct | 125,317 |
Reported balance
After 2022-06-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-06-09 · Other · Acquired 223 · Balance 125,317 F3: Expiration date of the stock options was extended to June 9, 2024. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $516.96 · Expires 2024-06-09 | Direct | 125,317 |
Reported balance
After 2022-06-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-06-09 · Other · Acquired 223 · Balance 125,317 F3: Expiration date of the stock options was extended to June 9, 2024. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $316.08 · Expires 2024-06-09 | Direct | 125,317 |
Reported balance
After 2022-06-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-06-09 · Other · Acquired 195 · Balance 125,317 F3: Expiration date of the stock options was extended to June 9, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the Reporting Person's departure from the Board of Directors, the Compensation Committee accelerated the vesting of 26,800 stock options to June 9, 2022 from March 9, 2023. In addition, the Compensation Committee extended the expiration date of the stock options to June 9, 2024.
F2: In connection with the Reporting Person's departure from the Board of Directors, the Compensation Committee accelerated the vesting of 22,000 stock options to June 9, 2022 from June 10, 2022. In addition, the Compensation Committee extended the expiration date of the stock options to June 9, 2024.
F3: Expiration date of the stock options was extended to June 9, 2024.
Hepion Pharmaceuticals, Inc.
Report date February 19, 2024 · Filed February 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.56 · Expires 2034-02-19 | Direct | 99,563 |
Reported balance
After 2024-02-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-19 · Grant · Acquired 85,000 · Balance 99,563 |
OKYO Pharma Ltd
Report date July 21, 2026 · Filed August 07, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 35,201 |
Reported balance
After 2026-07-21 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-07-21 · Purchase · Acquired 5,000 · Balance 35,201 |
SYNERGY PHARMACEUTICALS, INC.
Report date July 04, 2018 · Filed July 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,571 |
Ending reported balance
After 2018-07-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-07-04 · Exercise / conversion · Acquired 50,023 · Balance 130,467 Row 2 · 2018-07-04 · Tax withholding · Disposed 13,896 · Balance 116,571 F1: Represents the number of shares forfeited to the Company in payment of the exercise price of the stock options. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2018-07-09 | Direct | 506,173 |
Reported balance
After 2018-07-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-07-04 · Exercise / conversion · Disposed 50,023 · Balance 506,173 F2: Options became exercisable on 7/9/2009 and 7/9/2010. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares forfeited to the Company in payment of the exercise price of the stock options.
F2: Options became exercisable on 7/9/2009 and 7/9/2010.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2016 Filed Sep 21, 2016 20:31 UTC | SYNERGY PHARMACEUTICALS, INC. SGYP · Entity 164269 | SaleCommon Stock | 2,518 | $5.76 | $14,503.68 |
DisclosureSEC source: 0001104659-16-145907 · a4.xml · nonDerivative · entry 3 BRANCACCIO JOHN P · CIK 0001276551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,444 Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 20:31 UTC | SYNERGY PHARMACEUTICALS, INC. SGYP · Entity 164269 | Exercise / conversionCommon Stock | 1,079 | $4.28 | $4,618.12 |
DisclosureSEC source: 0001104659-16-145907 · a4.xml · nonDerivative · entry 2 BRANCACCIO JOHN P · CIK 0001276551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 20:31 UTC | SYNERGY PHARMACEUTICALS, INC. SGYP · Entity 164269 | Exercise / conversionCommon Stock | 1,439 | $4.61 | $6,633.79 |
DisclosureSEC source: 0001104659-16-145907 · a4.xml · nonDerivative · entry 1 BRANCACCIO JOHN P · CIK 0001276551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.